losartan has been researched along with Gout in 17 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Gout: Metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of URIC ACID calculi.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although allopurinol has been available for approximately 50 years, hyperuricemia and its sequelae are not only prevalent, but the incidence and costs associated with this disorder continue to increase." | 8.82 | Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. ( Bomalaski, JS; Clark, MA, 2004) |
| "To report a case of angioedema associated with losartan administration." | 7.70 | Losartan-induced angioedema. ( Rivera, JO, 1999) |
| "Losartan has been shown to increase urinary uric acid excretion and hence to lower serum uric acid levels." | 6.70 | Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. ( Brunner, HR; Burnier, M; Chiolero, A; Fallab-Stubi, CL; Gerster, JC; Maillard, M; Würzner, G, 2001) |
| "Although allopurinol has been available for approximately 50 years, hyperuricemia and its sequelae are not only prevalent, but the incidence and costs associated with this disorder continue to increase." | 4.82 | Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. ( Bomalaski, JS; Clark, MA, 2004) |
| "To report a case of angioedema associated with losartan administration." | 3.70 | Losartan-induced angioedema. ( Rivera, JO, 1999) |
| "Losartan has been shown to increase urinary uric acid excretion and hence to lower serum uric acid levels." | 2.70 | Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. ( Brunner, HR; Burnier, M; Chiolero, A; Fallab-Stubi, CL; Gerster, JC; Maillard, M; Würzner, G, 2001) |
| "Gout is increasing worldwide." | 2.49 | Hypertension, its treatment, hyperuricaemia and gout. ( Gibson, TJ, 2013) |
| "Diagnosis of gout is established when typical monosodium urate crystals can be identified." | 2.44 | [Involvement of the foot in metabolic diseases]. ( Gerster, JC, 2007) |
| "Thus, the treatment of hypertension and hyperlipidemia associated with hyperuricemia is also important." | 2.44 | [Other antihyperuricemic agents]. ( Hisatome, I; Igawa, O; Ogino, K, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Saad, M | 1 |
| Castilla-Ojo, N | 1 |
| Turkson-Ocran, RA | 1 |
| Conlin, PR | 1 |
| Appel, LJ | 1 |
| Miller, ER | 1 |
| Juraschek, SP | 1 |
| Ashcroft, JA | 1 |
| Saar, J | 1 |
| Kirch, W | 1 |
| Vatseba, MO | 1 |
| Bundrick, JB | 1 |
| Litin, SC | 1 |
| Perez-Ruiz, F | 2 |
| Herrero-Beites, AM | 1 |
| Carmona, L | 1 |
| Gibson, TJ | 1 |
| Bomalaski, JS | 1 |
| Clark, MA | 1 |
| Tatsuno, I | 1 |
| Gerster, JC | 2 |
| Ogino, K | 1 |
| Igawa, O | 1 |
| Hisatome, I | 1 |
| Jones, RE | 1 |
| Ball, EV | 1 |
| Rivera, JO | 1 |
| Würzner, G | 1 |
| Chiolero, A | 1 |
| Maillard, M | 1 |
| Fallab-Stubi, CL | 1 |
| Brunner, HR | 1 |
| Burnier, M | 1 |
| Liberopoulos, E | 1 |
| Christides, D | 1 |
| Elisaf, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies: a Cross-over Randomized Clinical Trail[NCT05402397] | Phase 4 | 40 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for losartan and Gout
| Article | Year |
|---|---|
Hypertension, its treatment, hyperuricaemia and gout.
Topics: Antihypertensive Agents; Blood Pressure; Diuretics; Female; Gout; Humans; Hypertension; Hyperuricemi | 2013 |
Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
Topics: Allopurinol; Amlodipine; Clinical Trials as Topic; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hype | 2004 |
[Hyperuricemia in hypertension].
Topics: Animals; Antihypertensive Agents; Arteriosclerosis; Calcium Channel Blockers; Diet, Sodium-Restricte | 2004 |
[Involvement of the foot in metabolic diseases].
Topics: Achilles Tendon; Acute Disease; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Apatites; Chon | 2007 |
[Other antihyperuricemic agents].
Topics: Antihypertensive Agents; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Gout; Gout | 2008 |
2 trials available for losartan and Gout
| Article | Year |
|---|---|
Effects of the DASH diet and losartan on serum urate among adults with hypertension: Results of a randomized trial.
Topics: Adult; Dietary Approaches To Stop Hypertension; Female; Gout; Humans; Hypertension; Hyperuricemia; L | 2023 |
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Chronic Disease; Cross-Over Studies; Double-Blind | 2001 |
10 other studies available for losartan and Gout
| Article | Year |
|---|---|
Hyperuricemia and Gout: The Role of Losartan.
Topics: Antihypertensive Agents; Gout; Humans; Hyperuricemia; Losartan | 2023 |
Alternatives to specific uric acid lowering treatment in gout in patients with cardiovascular disease.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Calcium Channel Blockers; Cardiov | 2018 |
[A new application for well-known pharmaceutics--losartan and fenofibrate as potential remedies against gout?].
Topics: Angiotensin II Type 1 Receptor Blockers; Fenofibrate; Gout; Gout Suppressants; Humans; Hypolipidemic | 2014 |
[Endothelial dysfunction as a marker of vascular aging syndrome on the background of hypertension, coronary heart disease, gout and obesity].
Topics: Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Cardiovascular Agents; Carotid Arterie | 2013 |
Clinical pearls in general internal medicine.
Topics: Abdominal Pain; Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Androgen Antagonists; Anti-Inf | 2011 |
A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.
Topics: Aged; Cohort Studies; Colchicine; Crystallization; Female; Fenofibrate; Follow-Up Studies; Gout; Gou | 2011 |
New treatments for gout.
Topics: Allopurinol; Ascorbic Acid; Female; Fenofibrate; Gout; Gout Suppressants; Humans; Losartan; Male; Se | 2007 |
Gout: beyond the stereotype.
Topics: Aged; Algorithms; Allopurinol; Chronic Disease; Diagnosis, Differential; Female; Gout; Gout Suppress | 1999 |
Losartan-induced angioedema.
Topics: Angioedema; Antihypertensive Agents; Gout; Humans; Hypertension; Losartan; Male; Middle Aged | 1999 |
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout.
Topics: Antihypertensive Agents; Biphenyl Compounds; Gout; Humans; Hypertension; Irbesartan; Losartan; Tetra | 2002 |